Scott Durrance
Psychiatric/Mental Health · Pensacola, FLNPI 1154620185
Payments from drug & device makers
Across 738 payments — averaging $303.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$212K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$5K
- Biogen$2K
- Otsuka America Pharmaceutical, Inc.$1K
- AbbVie$912
- Alkermes, Inc.$630
- plus $3K from 23 others
What the payments were for
- Consulting fees$5,1822%
- Speaking & faculty fees$166,78175%
- Travel & lodging$39,22818%
- Food & beverage$12,3546%
- Education$2160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 329 | $211,702 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 49 | $4,740 |
| Biogen | 1 | $1,539 |
| Otsuka America Pharmaceutical, Inc. | 50 | $1,034 |
| AbbVie | 89 | $912 |
| Alkermes, Inc. | 23 | $630 |
| Neos Therapeutics, LP | 58 | $501 |
| Axsome Therapeutics, Inc. | 14 | $367 |
| Vanda Pharmaceuticals Inc. | 10 | $309 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $282 |
| Corium, LLC | 16 | $217 |
| Lundbeck LLC | 10 | $217 |
| Supernus Pharmaceuticals, Inc. | 13 | $199 |
| Ironshore Pharmaceuticals Inc. | 9 | $174 |
| Tris Pharma Inc | 9 | $153 |
| Almatica Pharma LLC | 8 | $151 |
| E.r. Squibb & Sons, L.L.C. | 5 | $132 |
| Bausch Health US, LLC | 4 | $86 |
| Teva Pharmaceuticals USA, Inc. | 3 | $78 |
| Collegium Pharmaceutical, Inc. | 4 | $68 |
| Merck | 3 | $50 |
| Adlon Therapeutics L.p. | 3 | $46 |
| Vivus LLC | 2 | $35 |
| Sunovion Pharmaceuticals Inc. | 4 | $35 |
| Idorsia Pharmaceuticals US Inc | 2 | $28 |
| Alfasigma USA, Inc. | 2 | $28 |
| Avanir Pharmaceuticals, Inc. | 1 | $20 |
| Eisai Inc. | 1 | $16 |
| Noven Therapeutics, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$143,934
- INVEGA TRINZA$142,730
- SPRAVATO$63,545
- CAPLYTA$3,789
- ARISTADA$468
- Fanapt$125
- Cotempla XR-ODT$119
- Adzenys XR-ODT$119
- ZolpiMist$119
- ARISTADA INITIO$117
- Auvelity$114
- ABILIFY MAINTENA$109
How this compares
$223,762 in reported general payments places this provider in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AuvelityDextromethorphan Hbr/Bupropion | 58 | $69,162 |
| AustedoDeutetrabenazine | 11 | $51,228 |
| VraylarCariprazine Hcl | 26 | $41,577 |
| RexultiBrexpiprazole | 20 | $32,454 |
| TrintellixVortioxetine Hydrobromide | 36 | $26,733 |
| LybalviOlanzapine/Samidorphan Malate | 17 | $25,685 |
| NeuproRotigotine | 11 | $9,294 |
| Adzenys Xr-OdtAmphetamine | 13 | $5,855 |
| XelstrymDextroamphetamine | 11 | $5,177 |
| Vilazodone Hcl | 40 | $3,832 |
| Methylphenidate ErMethylphenidate Hcl | 34 | $3,678 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 76 | $3,471 |
| Aripiprazole | 41 | $1,428 |
| Alprazolam | 236 | $1,301 |
| Quetiapine Fumarate | 46 | $1,106 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Axsome Therapeutics, Inc.Auvelity | $367 | $69,16258 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $78 | $51,22811 claims |
| AbbVieVraylar | $912 | $41,57726 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,034 | $32,45420 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $282 | $26,73336 claims |
| Alkermes, Inc.Lybalvi | $630 | $25,68517 claims |
| Neos Therapeutics, LPAdzenys Xr-Odt | $501 | $5,85513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.
Other psychiatric/mental health in Pensacola
- Rohona MascharakPensacola$42K
- Leif SternungPensacola$15K
- Roger RiveraKissimmee$1.6M
- Bethanie Simmons BecilJacksonville$782K
- Hannah PhillipsMaitland$455K
- Cheedy JajaTampa$266K
- Eudaldo AponteHialeah$214K
- Heather WarrenTallahassee$172K
- Angela DavenportAlachua$83K
- Natalie MoodyWinter Haven$75K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.